Hims & Hers Health (NYSE:HIMS) Downgraded to Neutral by Citigroup

Citigroup lowered the company’s shares Health Hims and Hers (NYSE:HIMS – Free Report) from a buy rating to neutral in a report published Wednesday morning, MarketBeat.com reports. Citigroup now has a $20.00 price target on the stock, up from the prior price target of $16.00.

Several other brokerages have also recently published reports on HIMS. SVB Leerink began covering the Hims & Hers Health stock in a report on Monday, February 26. They issued a market rating and price target for the stock of $10.00. Imperial Capital upgraded Hims & Hers Health from an in-line rating to an outperform rating and set the target price for the company’s shares at $16.00 in a report dated Wednesday, February 28. On Monday, February 26, Leerink Partners re-issued its Market Performance Assessment for shares of Hims & Hers Health. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a hold rating in a research note on Tuesday, May 7. Finally, Truist Financial increased their price target on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a research note on Tuesday, February 27th. Seven investment analysts rated the company with a hold rating and eight with a buy rating. Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus price target of $15.69, according to MarketBeat.com.

Read our latest report on HIMS

Hims & Hers Health Price Results

On Wednesday, the NYSE HIMS opened at $16.18. The company has a 50-day moving average price of $14.08 and a 200-day moving average price of $11.01. The company’s market capitalization is $3.48 billion, its P/E ratio is -1,618.00, and its beta is 0.97. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $20.11.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, $0.03 above analyst consensus estimates of $0.02. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million for the quarter, compared to analyst expectations of $270.37 million. During the same quarter last year, the company reported earnings per share ($0.05). The company’s revenue for the quarter was up 45.8% year-over-year. On average, analysts expect Hims & Hers Health to post 0.18 earnings per share for the current fiscal year.

Buying and selling confidential information

In other Hims & Hers Health news, whistleblower Irene Becklund sold 2,747 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $12.08 for a total transaction of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at $66,367.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction amount of $39,171.95. Following the transaction, the insider now owns 166,866 shares of the company’s stock, valued at approximately $2,611,452.90. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which can be accessed at this hyperlink. Additionally, on Tuesday, February 27, whistleblower Irene Becklund sold 2,747 shares of the company’s stock as part of a transaction. The shares were sold at an average price of $12.08 for a total value of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at $66,367.52. The announcement of this sale can be found here. Over the last ninety days, insiders have sold 594,553 shares of company stock worth $8,454,738. Currently, 17.71% of the shares are owned by company insiders.

Institutional investors are assessing his and her health

Several institutional investors and hedge funds have recently modified their holdings in the stock. FNY Investment Advisers LLC acquired a new position in Hims & Hers Health during the fourth quarter worth approximately $48,000. Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth $76,000. EMC Capital Management increased its stake in shares of Hims & Hers Health by 80.0% during the third quarter. After purchasing an additional 5,332 shares of stock during the period, EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000. Certuity LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at $109,000. Finally, in the third quarter, Corton Capital Inc. purchased new shares in Hims & Hers Health worth USD 122,000. Hedge funds and other institutional investors hold 63.52% of the company’s shares.

About his and her health

(Get the free report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers with licensed health care professionals in the United States, United Kingdom and around the world. The company offers a range of selected prescription and over-the-counter health and wellness products and services that customers can purchase directly on its websites and mobile app.

See also

Get his and her health news and ratings every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.